Ah, a change of tactic, ground attack now.Versatile company. Excellent news, have had shares for some 5 years. Good plan and good managers. Doc
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%